Pools of factor XIII (FXIII) exist in the plasma and within the cytoplasm of hematopoietic cells, including platelets. The functions of the cellular form, FXIII-A, have been assumed to be intracellular in nature, as the protein lacks a signal sequence for its release. Mounting evidence now suggests that platelet FXIII-A modulates hemostasis by several different mechanisms. In this condensed review we discuss recent advances in our understanding of the novel intracellular and extracellular functions of platelet FXIII-A.
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Background
Factor XIIIa (FXIIIa; E.C. 2.3.2.13) is a glutaminyl-peptide γ-glutamyl transferase that functions to stabilize fibrin against mechanical stress and proteolytic degradation.
FXIII circulates in plasma as a tetramer composed of two pairs of non-identical subunits; the A2 subunits, containing the active site and the carrier B2 subunits [1] .
Cleavage of FXIII-A2B2 by thrombin in the presence of Ca 2+ permits dissociation of the carrier B subunits and exposure of the active site cysteine generating an active transglutaminase enzyme, FXIIIa [2, 3] . FXIIIa is unique in its classification as a coagulation factor, as it is the only non-proteolytic enzyme within the cascade.
Cross-linking of fibrin and inhibitors by FXIIIa
Activated FXIII crosslinks substrates via formation of ε-(γ-glutamyl) lysyl isopeptide bonds [4] . Numerous factor XIII substrates have now been identified, including a number of platelet-derived proteins such as actin, glycoprotein 1b and other cytoskeletal elements [5] [6] [7] [8] [9] [10] . This review will centre on cross-linking of fibrin and inhibitors of fibrinolysis. The initial cross-links that form in fibrin arise rapidly between γ-chains of neighbouring fibrin molecules [11] with subsequent high molecular weight polymers forming upon α-chain cross-linking [3, 12] . Cross-linking has a direct impact on the rheological properties of fibrin, enhancing clot rigidity and stabilizing against mechanical stress [13, 14] . FXIIIa also cross-links several inhibitors of fibrinolysis to fibrin, namely α2-antiplasmin (α2AP) [15] , thrombin activatable fibrinolysis inhibitor [16] and plasminogen activator inhibitor-2 [17] . The influence of cross-linking on inhibition of fibrinolysis is difficult to visualise using conventional in vitro models, such as clot lysis. However, using a flow-based model
we were able to demonstrate a direct effect of FXIIIa in down-regulating thrombus lysis [18] . α2AP is the principal fast acting inhibitor of the fibrinolytic protease plasmin [19] and is cross-linked via Gln-2 to Lys-303 of the Aα chain of fibrin(ogen) by FXIIIa [20] . Neutralization or deficiency of α2AP dramatically impacts the susceptibility of thrombi to fibrinolysis [15, 21, 22] . Using flow we revealed that the antifibrinolytic function of FXIIIa is exclusively mediated via cross-linking of α2AP to fibrin, with thrombi that lack either FXIII or α2AP lysing at strikingly similar rates [23] .
Cellular FXIII-A
FXIII exists in a cellular form (FXIII-A) within the cytoplasm of several haematopoietic cells including platelets [1, [24] [25] [26] [27] [28] [29] megakaryocytes [30] , monocytes [31, 32] , circulating [33] and tissue macrophages [32] . Platelets contain an abundance of FXIII [34] predominantly within their cytoplasm, as a homodimer of FXIII-A [26, 27] , however a small pool of the A2B2 form is reported to exist within α-granules [26, 35] .
The source of α-granule FXIII is plasmatic, as the A2B2 form circulates bound to fibrinogen and both are simultaneously endocytosed by platelets [35] . Early studies indicated that platelet FXIII-A is retained in the cytoplasm following activation and is not detectable in the platelet secretome [36] . FXIII-A does not contain an identifiable endoplasmic reticulum (ER) signalling sequence and is excluded from the ER-Golgi pathway in nucleated cells [37] . However, it has been found to be directed toward the plasma membrane in association with Golgi vesicles in monocyte-macrophages [38] . Due to the lack of ER-leader sequence FXIII-A cannot be targeted to α-granules in nascent platelets during de novo synthesis in megakaryocytes. This has led to the assumption that the functions of platelet FXIII-A are intracellular and distinct from the role of the plasma A2B2 form of FXIII in hemostasis.
Intracellular roles of platelet FXIII-A
Activation of platelets by conventional agonists generates a rapid spike in intracellular Ca 2+ [39] , where concentrations above 2 mM [40] enable non-proteolytic activation of FXIII-A [41] . Platelet FXIII-A has been implicated in several intracellular-mediated processes, including clot retraction. This dynamic process involves the reorganisation of proteins and structures at intra-and extracellular level and bidirectional signalling via the integrin, αIIbβ3. Initially, inside-out signalling induces a conformational change in αIIbβ3 allowing it to bind extracellular fibrin(ogen) [42] . Once in place the ligand triggers αIIbβ3-mediated outside-in signalling [43] which connects to the actin cytoskeleton via talin [44] . The actin cytoskeleton then effectively acts as a winch to reel in the fibrin coupled to the extracellular portion of the receptor via platelet pseudopodia. Plasma FXIII also facilitates clot retraction by cross-linking extracellular fibrin, thereby increasing network rigidity, and by enhancing platelet spreading [45] . Clot retraction is significantly impaired in the absence of platelet FXIII-A transglutaminase activity [46, 47] . Platelet FXIII-A also cross-links intracellular cytoskeletal proteins [6] [7] [8] [9] [10] and regulates reorganisation of the activated platelet cytoskeleton and αIIbβ3 via sphingomyelin-rich lipid rafts, which act as the axis between intracellular and extracellular clot retraction mechanisms [46] .
During thrombus formation different subpopulations of platelets arise [48] which display distinct phenotypic characteristics and play diverse roles within the microenvironment of the thrombus. Adherent platelets, with activated αIIbβ3, facilitate platelet-platelet interaction and binding to fibrin thereby augmenting thrombus stability [48] . Phosphatidylserine (PS)-exposing procoagulant platelets promote thrombin generation and further fibrin formation [49] . Platelet FXIII-A and calpain have been implicated in the adhesive capacity of αIIbβ3 in procoagulant platelets thereby regulating thrombus size [50] . Formation of the highly procoagulant 'coated' platelets is also regulated by transglutaminase activity, which cross-links α-granule proteins, such as platelet factor V, to serotonin on the activated platelet surface [51, 52] . Jobe et al [53] demonstrated that FXIII was dispensable for coated platelet formation in mice. Interestingly, these FXIIIA -/-mice demonstrated increased transglutaminase activity in platelet lysates, suggestive of a compensatory mechanism by another transglutaminase. Recent findings confirmed the contribution of tranglutaminase and highlighted a role for the integrin αIIbβ3 in coated platelet formation and in subsequent platelet-dependent fibrin formation [54] .
Extracellular functions of platelet FXIII-A
Early studies on the antifibrinolytic function of platelet FXIII-A identified that platelets mediated stabilization of clots [55] , induced high molecular weight γ-dimer and α-polymer formation [55] [56] [57] [58] [59] and cross-linked α2AP to fibrin [56, 57] . Despite these studies implicating platelet FXIII-A in extracellular hemostasis events there was no direct evidence illustrating its release from platelets. Our recent work has shown that platelet FXIII-A is undetectable in the platelet secretome, as previously reported [36] , but is externalized onto the outer membrane of activated platelets [60] . Intriguingly, the distribution of FXIII-A on the activated platelet membrane depends on the subpopulation of platelets; with PS-negative, adherent platelets displaying a diffuse distribution, while PS-positive, procoagulant platelets expose FXIII-A in a single protruding 'cap' (Figure 1) [60] . These 'caps' have previously been shown to bind fibrinogen [61] and we have shown that they harbour other proteins including plasminogen and PAI-1 [62] . The reduction in the adhesive ability of αIIbβ3 by FXIII-A [50] combined with the clustering of fibrinolytic proteins in the 'caps' of these procoagulant platelets suggest they may function in regulating thrombus stability.
We found that thrombi formed from FXIII-deficient plasma were stabilized by the addition of platelets in a transglutaminase-dependent manner [60] . In order to protect against fibrinolysis functional α2AP was required, indicating that platelet FXIII-A actively participates in extracellular cross-linking reactions [60] .
Surface exposure and cross-linking by platelet FXIII-A was only evident following platelet activation and coincided with translocation from the cytoplasm to the outer leaflet of the membrane [60] . The exact signalling mechanisms involved are still to be defined, but it is likely that the previously described interactions of FXIII-A with intracellular clot retraction machinery [6] [7] [8] [9] [10] , lipid rafts [46] and αIIbβ3 are crucial to its externalization upon platelet activation (Figure 2 ). FXIII-A activity was also evident with thrombin receptor activation peptide 6 (TRAP-6)-mediated platelet activation, confirming that activation from the protransglutaminase to functional transglutaminase does not require thrombin and arises from the spike in intracellular Ca 2+ upon activation. Interestingly, inhibition of fibrin polymerisation with Gly-ProArg-Pro, or activation of platelets by TRAP-6 in place of thrombin reduced the number of FXIII-A-positive platelets. These data imply that platelet-bound fibrin participates in the retention of FXIII-A and possibly serves as an anchor-point for transfer of FXIII-A into the adjacent fibrin network allowing participation in extracellular cross-linking reactions [60] . It has been shown that FXIII-A binds to the αC domain (residues 389-402) of fibrin(ogen) via both its active site [63] and its activation peptide cleft thereby promoting crosslinking of fibrin and α2AP [64] . It is plausible that upon platelet activation FXIII-A will bind to platelet-bound fibrin via these two sites. In accordance with this the fibrin network immediately adjacent to the surface of activated platelets is extremely resistant to fibrinolysis [62, [65] [66] [67] [68] .
The antifibrinolytic function of platelet FXIII-A may be central in stabilizing thrombi in certain situations, such as during surgery when plasma FXIII-A2B2 levels rapidly decline [69] or following cardiopulmonary bypass with extracorporeal circuit.
Acquired FXIII deficiency can also occur in the case of major trauma where plasma FXIII-A2B2 levels deplete to around 30-35% of normal [70] . FXIII-B subunit deficiency leads to dramatic reduction in FXIII-A concentration in plasma, due to its instability [71] [72] [73] , however platelet FXIII-A levels are normal [72, 74] . FXIII-B deficiency is less severe than FXIII-A deficiency [71, 75] which is attributed to remaining circulating FXIII-A in plasma. Our results indicate that platelet FXIII-A may contribute to thrombus stabilization in these situations. We show that when plasma FXIII-A2B2 is below 20% of normal the antifibrinolytic effect of platelet FXIII-A becomes apparent [60] .
Concluding remarks
Clearly the role of platelet FXIII-A has been markedly underestimated with a mounting body of evidence highlighting its importance in modulating platelet phenotype [50] [51] [52] , facilitating the intracellular elements of clot retraction [46, 47] and mediating extracellular cross-linking reactions [60] . These reports illustrate that FXIII-A has diverse and crucial functions in thrombus formation and stability. Further work is required to tease out the importance of platelet FXIII-A in relation to plasmaderived FXIII and whether these enzymes play functionally distinct but overlapping roles in hemostasis. There are also multiple questions related to the signalling events involved in the externalisation of cytoplasmic FXIII-A on the stimulated platelet membrane and its ability to actively diffuse into the surrounding fibrin network; as suggested by its ability to cross-link extracellular substrates (Figure 2 ).
These observations and insights into the functions of platelet FXIII-A underscore the seamless transition between intracellular and extracellular events that modulate thrombus formation and stability in vivo. Plasma FXIII enhances clot retraction extracellularly by cross-linking fibrin thereby providing further rigidity to the network and allowing enhanced platelet spreading.
